Krystal Biotech Inc (KRYS)

Operating return on assets (Operating ROA)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Operating income (ttm)	US$ in thousands	-67,587	-109,726	-147,635	-153,093	-143,798	-145,197	-132,302	-116,503	-104,143	-68,274	-56,818	-50,846	-41,407	-33,000	-28,734	-24,396	-23,332	-22,080	-18,898	-16,005
Total assets	US$ in thousands	853,296	818,355	790,350	684,026	531,847	558,450	576,379	601,324	616,874	626,295	451,095	443,556	443,018	310,844	311,451	318,145	205,131	209,023	214,232	205,156
Operating ROA		-7.92%	-13.41%	-18.68%	-22.38%	-27.04%	-26.00%	-22.95%	-19.37%	-16.88%	-10.90%	-12.60%	-11.46%	-9.35%	-10.62%	-9.23%	-7.67%	-11.37%	-10.56%	-8.82%	-7.80%

March 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $-67,587K ÷ $853,296K
= -7.92%

Krystal Biotech Inc's operating return on assets (operating ROA) has shown a declining trend over the past few quarters, indicating challenges in generating profits from its operating activities relative to its total assets. The negative percentages suggest that the company's operating profits are insufficient to cover the asset base, resulting in operating losses.

The trend of decreasing operating ROA from -7.92% in March 2024 to -27.04% in March 2023 highlights a worsening profitability performance during this period. The lowest point reached in March 2023 indicates significant difficulties in effectively utilizing its assets to generate operating income.

Overall, the consistently negative operating ROA figures suggest that Krystal Biotech Inc needs to address inefficiencies in its operations to improve profitability and asset utilization. Investors and stakeholders may monitor the company's efforts to enhance operational efficiency and boost returns on assets in the future.